Identification

Summary

Chymotrypsin is a digestive enzyme supplement used as supportive therapy to manage the side effects associated with conventional chemotherapy, radiotherapy, and hormone therapy.

Generic Name
Chymotrypsin
DrugBank Accession Number
DB09375
Background

Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence of Trypsin. Chymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas 1. Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin is similar to Trypsin 3.

Type
Small Molecule
Groups
Approved, Vet approved
Synonyms
  • alpha-Chymotrypsin
  • Chymotrypsin
  • Chymotrypsin A
  • Chymotrypsin B
  • Chymotrypsine
  • Chymotrypsinum
  • Quimotripsina

Pharmacology

Indication

No therapeutic indications.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Chymotrypsin is a digestive enzyme synthesized in the pancreas that plays an essential role in proteolysis, or the breakdown of proteins and polypeptides. As a component in the pancreatic juice, chymotrypsin aids in the digestion of proteins in the duodenum by preferentially cleaving peptide amide bonds.

Mechanism of action

Chymotrypsin is synthesized by pancreatic acinar cells as an inactive precursor, chymotrypsinogen, that is secreted to the duodenum and activated via trypsin-induced cleavage. It also induces its own activation by cleaving essential amino acid residues in the oxyanion hole to produce α-Chymotrypsin, which is a more stable form than π-Chymotrypsin. Residues His-57, Asp-102, and Ser-195 form the catalytic triad while residues 189–195, 214–220, and 225–228 form the primary substrate-binding pocket called S1 binding pocket 3. Residue 189 in the polar serine residue that lies at the bottom of the S1 binding pocket 3. Chymotrypsin favors aromatic residues like phenylalanine, tyrosine, and tryptophan 3 but may hydrolyze other bonds in peptides at slower rates.

Absorption

No pharmacokinetic data available.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

No pharmacokinetic data available.

Route of elimination

No pharmacokinetic data available.

Half-life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

No toxicokinetic data available.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetylcysteineThe therapeutic efficacy of Acetylcysteine can be decreased when used in combination with Chymotrypsin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Catarase Pws 300units/2mlPowder, for solution300 unit / 2 mLOphthalmicIolab Pharmaceuticals1988-12-311997-07-23Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Wobenzym magensaftresistente TablettenChymotrypsin (300 FIP units) + Bromelains (225 FIP units) + Pancrelipase (300 protease units) + Papain (164 FIP units) + Rutoside trihydrate (50 mg) + Trypsin (720 FIP units)Tablet, delayed releaseOralMucos Pharma Gmb H & Co.Kg1984-03-30Not applicableAustria flag

Categories

ATC Codes
S01KX01 — ChymotrypsinB06AA04 — Chymotrypsin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
BVS505O332
CAS number
9004-07-3

References

General References
  1. Reseland JE, Larsen F, Solheim J, Eriksen JA, Hanssen LE, Prydz H: A novel human chymotrypsin-like digestive enzyme. J Biol Chem. 1997 Mar 21;272(12):8099-104. [Article]
  2. Di Cera E: Serine proteases. IUBMB Life. 2009 May;61(5):510-5. doi: 10.1002/iub.186. [Article]
  3. Ma W, Tang C, Lai L: Specificity of trypsin and chymotrypsin: loop-motion-controlled dynamic correlation as a determinant. Biophys J. 2005 Aug;89(2):1183-93. doi: 10.1529/biophysj.104.057158. Epub 2005 May 27. [Article]
KEGG Drug
D03484
PubChem Substance
347910449
RxNav
2530
ChEMBL
CHEMBL1201465
Wikipedia
Chymotrypsin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionOphthalmic300 unit / 2 mL
Tablet, delayed releaseOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 30, 2015 19:10 / Updated at May 14, 2021 01:05